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Objectives: Cefazolin is frequently administered for antimicrobial prophylaxis and treatment of infections. In neo-
nates, pharmacokinetic observations are limited and dosing regimens variable. The aim of this study was to
describe the pharmacokinetics of cefazolin in neonates based on total and unbound concentrations to optimize
cefazolin dosing.
Methods: Thirty-six neonates [median birth body weight 2720 (range 540–4200) g, current body weight (cBW)
2755 (830–4200) g and postnatal age (PNA) 9 (1–30) days] receiving intravenous cefazolin (50 mg/kg/8 h) were
included. Based on 119 total and unbound plasma concentrations, a population pharmacokinetic analysis with a
covariate analysis was performed. Monte Carlo simulations were performed aiming for unbound concentrations
above an MIC of 8 mg/L (.60% of the time) in all patients.
Results: A one-compartment pharmacokinetic model was developed in which total and unbound concentrations
were linked by maximum protein binding (Bmax) of 136 mg/L and a dissociation constant (KD) for cefazolin protein
binding of 46.5 mg/L. cBW was identified as covariate for volume of distribution (V), bBW and PNA for clearance
and albumin plasma concentration for Bmax, explaining 50%, 58% and 41% of inter-individual variability in V,
clearance and Bmax, respectively. Based on Monte Carlo simulations, a body weight- and PNA-adapted dosing
regimen that resulted in similar exposure across different weight and age groups was proposed.
Conclusions: A neonatal pharmacokinetic model taking into account total and unbound cefazolin concentrations
with saturable plasma protein binding was identified. As cBWand PNA were the most important covariates, these
may be used for individualized dosing in neonates.
Keywords: developmental pharmacology, antibiotics, protein binding
Introduction
Based on a European survey, 15% of antimicrobial use for surgical
prophylaxis in children is accounted for by first-generation cepha-
losporins.1 In a US point prevalence survey of patients in paediatric
intensive care units and neonatal intensive care units, cefazolin
was used in 17.6% and 1.2% of patients on the day of the survey,
respectively.2 Indications for cefazolin administration in neonates
are mainly prophylactic (72%), and to a lesser extent therapeutic
(17%) (e.g. coagulase-negative staphylococcal sepsis)3 or empir-
ical (11%).2 While the pharmacokinetics of cefazolin have been
described in adults, information on cefazolin pharmacokinetics
in early life is limited.4 – 6 Cefazolin is highly bound to human
serum albumin and this binding displays saturation.7 – 9 Only the
unbound cefazolin distributes to the extravascular compartments
and undergoes renal elimination. Neonates have a proportionally
large total body water volume, immature renal function and low
albumin level.10 – 12 This population-specific physiology probably
affects cefazolin disposition.
Efficacy of cefazolin relates to the time unbound cefazolin con-
centrations exceed the MIC for a given pathogen (T.MIC).
13 In neo-
nates, often regarded as vulnerable and even immunocompromised
patients, effective cefazolin therapy requires at least 60% of
T.MIC.
14
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Up to now, the neonatal clearance (CL) values for cefazolin
described in the literature are based on total cefazolin concentra-
tions only, necessitating a cefazolin pharmacokinetic analysis
integrating both total and unbound drug concentrations in neo-
nates. Moreover, currently used cefazolin dosing regimens for
neonates are variable (Table S1, available as Supplementary
data at JAC Online).15 – 21
Therefore, the aim of this study was to describe the pharmaco-
kinetics of cefazolin in preterm and term neonates on the basis of
both total and unbound cefazolin concentrations. Based on the final
pharmacokinetic model, Monte Carlo simulations were performed
to illustrate exposure to cefazolin in (pre)term neonates following
currently used dosing regimens. Subsequently, a model-based dos-
ing regimen was developed for preterm and term neonates.
Methods
Ethics, study population and drug dosing
Inclusion of patients in this study was based on a previously published
cohort of 39 neonates and young infants, all admitted to the Neonatal
Intensive Care Unit of the University Hospitals Leuven Belgium.8 The
study was approved by the ethics board of the hospital and registered at
ClinicalTrials.gov (NCT01295606), and parental written informed consent
was obtained. Inclusion was feasible if cefazolin (Cefazolin Sandozw,
Sandoz, Vilvoorde, Belgium) was administered intravenously as routine
surgical prophylaxis. At induction of surgery, a cefazolin dose of
50 mg/kg was administered over 30 min. According to the local standard
of care (depending on foreign body implantation or contamination risk of
the procedure), additional cefazolin dose(s) of 50 mg/kg could be adminis-
tered every 8 h up to a maximum of 48 h. As in the present analysis only
neonates with postnatal age (PNA) 1–30 days were included, three
patients (PNA 48, 51 and 108 days) were excluded from the original data-
set.8 Clinical characteristics were extracted from the medical files.
Albuminaemia (g/L), indirect serum bilirubin concentrations (mg/dL) and
serum creatinine (mg/dL) registered in a time interval of 24 h before or
after the first cefazolin administration were collected. Plasma free fatty
acid concentrations were determined in samples at the end of the
study. Clinical characteristics of the study population are presented in
Table 1.
Blood sampling
Blood samples were collected in lithium–heparin tubes at fixed timepoints
of 0.5, 2, 4 and 8 h after the first cefazolin administration and subse-
quently at 8 h intervals prior to each scheduled cefazolin administration,
to determine total and unbound cefazolin concentrations. However, the
number of samples collected from each patient was limited since the pre-
defined total volume of blood available for sampling per patient was max-
imized to 1 mL/kg body weight. Blood samples (0.6 mL/sample) were
immediately centrifuged (5 min, 4500 rpm at 48C) and the resulting
0.3 mL of plasma was stored at 2208C in two aliquots of 0.15 mL.
Drug assay
Total and unbound cefazolin concentrations were determined by HPLC
after solid-phase column extraction. The initial method was developed
in our laboratory22 and adapted for measurement of cefazolin in small-
volume plasma samples.8 The lower limit of quantification for cefazolin
was 0.1 mg/L, with a coefficient of variation ,20%. Intra-assay precision
and accuracy averaged 3.9% and 5.5%, respectively. Inter-assay precision
and accuracy averaged 5.7% and 6.8%, respectively, which is in line with
FDA analytical recommendations.23,24
Biochemical assays
Albumin, indirect bilirubin and creatinine (enzymatic) were quantified with
a Roche Modular P analyser (Roche Diagnostics, Basel, Switzerland). Free
fatty acids were determined with a kit from DiaSys Diagnostic Systems
(Holzheim, Germany).
Population pharmacokinetic analysis
Model development
The population pharmacokinetic analysis was performed using the non-
linear mixed-effect modelling software NONMEM version 6.2 (Globomax
LLC, Hanover, MD, USA) using the first-order conditional estimation
method with the interaction option (FOCE-I). Tools used to visualize and
evaluate the model were S-Plus version 6.2.1 (Insightful, Seattle, WA,
USA) with NM.SP.interface version 05.03.01 (# LAP&P Consultants BV,
Leiden, The Netherlands), PsN and R (version 2.10.1).
The model-building process was performed in a stepwise manner: (i)
choice of the structural model; (ii) choice of the statistical sub-model;
(iii) choice of the covariate model; and (iv) model evaluation. Different
diagnostic tools were used to discriminate between the different mod-
els.25 A decrease in objective function value (OFV) of≥3.9 points was con-
sidered statistically significant (P,0.05 based on the x2 distribution, for
nested models). Furthermore, the goodness-of-fit plots were evaluated.
Finally, the total number of parameters, visual improvement of individual
plots, correlation matrix, CIs of parameter estimates, ill conditioning26 and
shrinkage27 were assessed.
Structural and statistical sub-model
One- and two-compartment pharmacokinetic models were fitted to both
total and unbound cefazolin concentrations using NONMEM VI, subroutine
ADVAN6, TOL¼3. Unbound cefazolin concentrations were related to total
cefazolin concentrations by the following equation, taking into account
non-linear protein binding:28
Cunbound = 12× (Ctotal − Bmax − KD)
+
NameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMe
(Ctotal − Bmax − KD)2 + 4× KD × C
√
total
(1)
In this equation Cunbound represents the unbound cefazolin concentration,
Ctotal the total cefazolin concentration, Bmax the maximum protein binding
and KD the dissociation constant.
Table 1. Clinical characteristics of the patients included in the study
Number of patients 36
Number of samples 119
bBW (g), median (range) 2720 (540–4200)
cBW (g), median (range) 2755 (830–4200)
PNA (days), median (range) 9 (1–30)
GA (weeks), median (range) 37 (24–40)
PMA (weeks), median (range) 38 (25–41)
Albumin (g/L), median (range) 34.5 (28.2–43.7)
Creatinine (mg/dL), median (range) 0.46 (0.26–1.03)
Free fatty acids (mmol/L), median (range) 0.08 (0–0.84)
Indirect bilirubin (mg/dL), median (range) 2.91 (0.1–11.13)
Gender (number of males/number of females) 22/14
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For the statistical sub-model, the inter-individual variability was
assumed to follow a log-normal distribution. For the intra-individual vari-
ability and residual error, we tested proportional, additive and combined
error models.
Covariate analysis
The following covariates were evaluated in the covariate analysis: birth
body weight [bBW (g); body weight on the day of birth], current body
weight [cBW (g); body weight on the day of blood sampling], PNA (days),
gestational age [GA (weeks)], postmenstrual age [PMA (weeks); combin-
ation of GA and PNA in weeks], albuminaemia (g/L), creatininaemia
(mg/dL), free fatty acids (mmol/L), indirect bilirubin (mg/dL) and gender.
Potential covariates were separately implemented in the model using a
linear or power equation:
Pi = Pp ×
Cov
CovMedian
( )k
(2)
In this equation Pi represents the individual parameter estimate of the ith
subject, Pp equals the population parameter estimate, Cov is the covariate
and k is the exponent, which was fixed at 1 for a linear function or was esti-
mated for a power function. Covariates were considered statistically sig-
nificant if the OFV decreased by ≥7.8 points (P,0.005). The covariate
causing the largest reduction in OFV was chosen as a basis to sequentially
explore the influence of additional covariates. The choice of the covariate
models was further evaluated as discussed under Model development,
whereby the results of the model validation were also considered.
Model validation
The stability of the final pharmacokinetic model was evaluated by a boot-
strap analysis, in which the model building dataset was resampled 1000
times in S-Plus version 6.2.1 with NM.SP.interface version 05.03.01. To
evaluate the accuracy of the model the normalized prediction distribution
error (NPDE) method was used. To perform this analysis the dataset was
simulated 1000 times, after which each observed concentration was com-
pared with the simulated concentrations using the NPDE package in R.29,30
Monte Carlo simulations
To evaluate T.MIC, the CLSI 2012
31 MIC interpretative criteria for suscepti-
bility to cefazolin corresponding to the five bacterial species isolated most
frequently from neonatal blood cultures from our department were used.
Therefore, all positive blood culture results (n¼137) from our unit for the
period from January to October 2012 were retrospectively collected.
Identification of bacterial isolates was done by use of MALDI Biotyper
(Bruker Daltonics, Bremen, Germany). Staphylococcus species contributed
94.4% of the top five isolates. Consequently, the CLSI MIC interpretative
criterion for susceptibility to cefazolin of Staphylococcus species (8 mg/L)
was used as the target MIC (Table 2).31
As effective cefazolin therapy is reported to require at least 60% of
T.MIC, the probability of attaining unbound cefazolin concentrations dur-
ing 60% of the dosing interval14 .8 mg/L was evaluated on the basis of
Monte Carlo simulations using the final pharmacokinetic model. These
Monte Carlo simulations were performed in 1000 individuals to evaluate
exposure to cefazolin in (pre)term neonates following the currently used
dosing regimen in this study and the dosing regimen proposed by the
Dutch Children’s Formulary.15 The covariates identified in the final phar-
macokinetic model were sampled from the original dataset taking into
account their correlation. Albumin was randomly generated according to
the observed distribution in these 36 neonates. For the simulations, cefa-
zolin doses were administered over 30 min every 8 h until 48 h after the
first dose. To evaluate the results of the Monte Carlo simulations, four dif-
ferent groups (group 1, PNA ≤7 days and cBW ≤2000 g; group 2, PNA
≤7 days and cBW .2000 g; group 3, PNA .7 days and cBW ≤2000 g;
and group 4, PNA .7 days, cBW .2000 g) were created. Based on these
results, a new model-based dosing regimen was proposed.
Results
Patients
The pharmacokinetic analysis was based on 119 plasma concen-
trations of cefazolin obtained in 36 (pre)term neonates with PNA
1–30 days. Median total and unbound cefazolin plasma concen-
trations were 101.09 (range 17.44–404.22) and 41.15 (range
5.34–261.38) mg/L, respectively. The median unbound fraction
was 0.40 (range 0.14–0.73). Clinical characteristics are presented
in Table 1.
Population pharmacokinetic analysis
Structural and statistical sub-model
A one-compartment model was selected as the structural model
because a two-compartment model was not superior to a one-
compartment model. The final one-compartment pharma-
cokinetic model, taking into account total and unbound cefazolin
concentrations, was parameterized in terms of CL, volume of dis-
tribution (V), Bmax and KD (Figure 1). By the determination of Bmax
and KD, unbound cefazolin concentrations could be calculated
from total concentrations (Equation 1). Initially, a separate pro-
portional error was estimated for total and unbound cefazolin
concentrations. Since these errors were not significantly different
Table 2. The five bacterial species isolated most frequently from neonatal blood cultures (n¼137) in the Leuven neonatal intensive care unit for the
period January 2012 to October 2012; corresponding CLSI MIC values are reported
Isolate
Contribution to all positive blood
cultures (%)
Contribution to top
five isolates (%)
CLSI MIC values (mg/L)
susceptible intermediate resistant
Staphylococcus epidermidis 51.82 65.74 ≤8 16 ≥32
Staphylococcus hominis 9.49 12.04 ≤8 16 ≥32
Staphylococcus aureus 6.57 8.33 ≤8 16 ≥32
Staphylococcus capitis 6.57 8.33 ≤8 16 ≥32
Escherichia coli 4.38 5.56 ≤2 4 ≥8
Cefazolin pharmacokinetics and dosing in neonates
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(P.0.05), the model was simplified by estimating one propor-
tional error for both total and unbound concentrations.
Covariate model
cBW was found to be the most important covariate on V. Initially,
cBW was implemented on V using a power function with an esti-
mated exponent of 0.94. However, since the 95% CI of this par-
ameter included 1, a linear relationship between cBW and V was
used (P.0.05). Implementation of cBW on V caused a significant
drop in OFV of 46 points (P,0.005). Although for CL, PMA was
identified as the most important covariate, a combination of the
covariates bBW and PNA was preferred over PMA alone. First, both
analyses resulted in a comparable improvement of the model (i.e.
same reduction in OFV of 32 points, P,0.005). Secondly, the com-
bination of bBW and PNA made it possible to distinguish between
the antenatal (bBW) and postnatal (PNA) maturation compo-
nents of cefazolin CL. bBW was implemented on CL using a
power function with an estimated exponent of 1.37, while PNA
was implemented using a linear function with an estimated
slope of 0.496 (Table 3). The model was further improved (reduc-
tion in OFV of 12 points, P,0.005) by introducing albumin on Bmax
using a linear function (Table 3).
The parameter estimates of the simple and final pharmacoki-
netic models and the values obtained from the bootstrap analysis
are provided in Table 3. In Figure 2, the observed versus predicted
concentrations are plotted for the total and unbound concentra-
tions, showing that the model adequately described the data. In
Figure S1 (available as Supplementary data at JAC Online), the
inter-individual variabilities in CL, V and Bmax are plotted against
the relevant covariates for the simple and final pharmacokinetic
models. A significant part of the inter-individual variability is
explained (Figure S1). This is also reflected in the decrease in the
estimates of inter-individual variability when comparing the sim-
ple and final pharmacokinetic models, which resulted in a
decrease of 50% in the inter-individual variability in V, 58% in CL
and 41% in Bmax (Table 3). In Figure 3 the observed and population
predicted bound and unbound cefazolin concentrations are plot-
ted, from which Bmax and the value for the unbound concentration
for which the binding was half-maximal (KD) could be derived.
Variations in population predicted bound and unbound cefazolin
Dose
compartment
FUKD
Bmax
CLunbound
Figure 1. Schematic representation of the pharmacokinetic model using
both total and unbound concentrations of cefazolin. FU, unbound
fraction of cefazolin; CLunbound, CL of unbound cefazolin.
Table 3. Model-based population pharmacokinetic parameter estimates and values obtained after bootstrap analysis
Parameter
Simple model without
covariates:
Final pharmacokinetic
covariate model:
Bootstrap final
pharmacokinetic model:
value (CV%) value (CV%) value (CV%)
Fixed effects
CL (L/h)¼CLp 0.229 (11.7) — —
CLp in CL¼CLp×(bBW/median)m×[1+ (PNA/median)×n] — 0.185 (12.8) 0.187 (13.3)
m — 1.37 (16.4) 1.41 (17.3)
n — 0.496 (38.5) 0.524 (44.5)
V (L)¼Vp 0.812 (3.0) — —
Vp in V¼Vp×(cBW/median) — 0.863 (3.55) 0.860 (3.63)
Bmax (mg/L)¼Bmaxp 143 (14.5) — —
Bmaxp in Bmax¼Bmaxp×(ALB/median) — 136 (12.6) 141 (14.5)
KD (mg/L)¼KDp 53.2 (22.9) 46.5 (20.9) 49.5 (24.1)
Inter-individual variability (v2)
v2 CL 0.535 (33.6) 0.163 (35.1) 0.149 (38.0)
v2 V 0.14 (29.1) 0.0259 (38.6) 0.0258 (43.2)
v2 Bmax 0.102 (41.0) 0.0367 (54.0) 0.0368 (56.7)
Residual variability (s2)
s2 (proportional) 0.0332 (22.1) 0.0351 (21.5) 0.0342 (22.5)
CLp, population value of CL for an individual with bBW of 2720 g and PNA of 9 days; Vp, population value of V for an individual with a cBW of 2755 g;
Bmaxp, population value for maximum protein concentration for an individual with an albumin concentration of 34.5 g/L; KDp, population value of KD; ALB,
concentration of albumin.
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concentrations can be explained by differences in cBW, bBW and
PNA of the subjects (Figure 3).
The number of binding sites on the albumin molecule was
derived from Bmax, which was corrected for the molecular weights
of albumin (67000 g/mol) and cefazolin (454.5 g/mol) (Equation
3) and the median albumin concentration (34.5 g/L) (Equation 4),
and was calculated to be 0.6.
Bmax = 0.136 g/L× 67 000 g/mol454.5 g/mol
( )
= 20 g/L (3)
Number of binding sites
20 g/L
34.5 g/L
( )
= 0.6 (4)
Model validation
The results of the bootstrap analysis (Table 3) show that the
median estimated values based on the resampled dataset were
within 10% of the values obtained in the final model. The NPDE
histograms follow the normal distribution, indicating the accuracy
of the final pharmacokinetic model (Figure 2). Furthermore, no
trend was seen in the NPDE versus time or versus predicted con-
centrations (figures not shown). The ill-conditioning number
(74.6) was far below the critical number of 1000, indicating that
the final pharmacokinetic model was not overparameterized.
Finally, h-shrinkage, expressed as a percentage, was identified
to be 9.8% for CL, 21.2% for V and 30% for Bmax.
Monte Carlo simulations
Concentration–time profiles following the currently used dosing
regimen, the dosing regimen proposed by the Dutch Children’s
Formulary and the new model-based dosing regimen (Table 4)
were predicted based on Monte Carlo simulations using the final
pharmacokinetic model (Figure 4). In Figure S2 (available as
Supplementary data at JAC Online), box plots illustrate the med-
ians and IQRs (5% to 95%) of the individual predicted concentra-
tions at 60% of the dosing interval after the first dose and after
the fourth or sixth dose. This illustrates that ,10% of the individ-
ual predicted concentrations at 60% of the dosing interval are
below an MIC of 8 mg/L. Relatively high cefazolin peak concentra-
tions were reached, particularly in neonates in groups 1, 2 and 3
following the dosing regimen used in the current study and in
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group 3 following the dosing regimen proposed by the Dutch
Children’s Formulary (Figure 4 and Figure S2). Therefore, a new
dosing regimen was advised based on the dosing regimen pro-
posed by the Dutch Children’s Formulary, but including a lower
dose for group 3 (Table 4). Using this dosing regimen, 0%, 1.2%,
0.7% and 1.0% of the individuals of groups 1, 2, 3 and 4, respect-
ively, would be exposed to concentrations,8 mg/L at 60% of the
dosing interval (Figure S2B).
Discussion
Neonatal cefazolin pharmacokinetic data are outdated since they
are mainly based on total drug concentrations collected in a lim-
ited number of subjects. We aimed to characterize cefazolin
pharmacokinetics and its covariates based on both total and
unbound drug concentrations. In our study, the median cefazolin
CL value (coefficient of variation, %) for a neonate with a bBW of
2720 g and PNA 9 days was 0.185 (12.8) L/h (i.e. 0.068 L/kg/h).
This is slightly higher than the earlier reported values of 0.53–
1.10 mL/kg/min (i.e. 0.032–0.066 L/kg/h) in 11 neonates receiv-
ing 30 mg/kg cefazolin intravenously. Since only the unbound
cefazolin is pharmacologically active and total drug concentra-
tions only partially reflect unbound concentrations (Figure 3),
we would like to emphasize that unbound concentrations need
to be measured instead of using estimated unbound concentra-
tions based on a fixed protein binding percentage. This is of espe-
cial relevance in highly protein-bound drugs.
PNA and bBW were the most important covariates of neonatal
cefazolin CL. This is in line with expectations, taking into account
the elimination of cefazolin by the renal route. Renal CL displays
maturation during early life and covariates bBW and PNA can
thereby reflect prenatal and postnatal maturation, respectively.32
Furthermore, age and body weight were earlier documented as CL
predictors of other b-lactams in neonates.33 – 36 We can only
hypothesize about factors affecting the remaining unexplained
cefazolin CL variability within the neonatal population. Possibly,
maturation of renal tubular activity is a contributing factor. Also
for other b-lactams (e.g. amoxicillin, flucloxacillin), the presence
of other elimination pathways in addition to glomerular filtration
rate, such as tubular secretion or non-renal CL routes, was sug-
gested earlier.33,37 Since only the unbound drug can be eliminated
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Figure 3. Relationship between the observed (squares) and model-based predicted (circles) bound and unbound cefazolin concentrations (mg/L) in 36
(pre)term neonates. Bmax (protein binding defined as the maximum estimated concentration bound to albumin) and KD (defined as the unbound
concentration, which corresponds to 50% of the maximum binding capacity) are illustrated.
Table 4. Dosing recommendations for cefazolin in preterm and term
neonates according to dosing regimens used in the current study, the
Dutch Children’s Formulary and a new model-based proposed dosing
regimen
Guideline
PNA
(days) cBW (g)
Dose
(mg/kg)
Interval
(h)
Used in the
current study
— — 50 8
Dutch Children’s
Formulary
≤7 ≤2000 25 12
≤7 .2000 50 12
8–28 50 8
Proposed dosing
regimen
≤7 ≤2000 25 12
≤7 .2000 50 12
8–28 ≤2000 25 8
8–28 .2000 50 8
For concentration–time profiles of these dosing regimens for neonates
with different clinical characteristics see Figure 4.
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and since compound-specific CL depends on compound-specific
protein binding, we want to stress here that the mean+SD protein
binding of flucloxacillin (74.5+3.1%) and in particular amoxicillin
(11.7+2.7%) is lower compared with cefazolin.34,38 Therefore,
results for amoxicillin and flucloxacillin may not be directly applic-
able to cefazolin.
The number of binding sites for cefazolin on the albumin mol-
ecule based on this analysis was calculated to be 0.6 (Equations 3
and 4), which corresponds well to the number of binding sites for
cefazolin on albumin previously found in the literature (0.7).7,39,40
We documented relatively high cefazolin plasma concentra-
tions based on a cefazolin dosing regimen of 50 mg/kg/8 h, admi-
nistered to all study patients. This is probably due to the absence
of any body weight- and/or age-adapted dosing. Simulation of the
dosing regimen proposed by the Dutch Children’s Formulary
resulted in lower cefazolin concentrations. However, based on
Figure 4 and Figure S2, the dose administered to neonates in
group 3 when using the Dutch Children’s Formulary still needs fur-
ther reduction. A new body weight- and age-based dosing regi-
men is suggested, derived from the dosing regimen proposed by
the Dutch Children’s Formulary, but with a dose reduction for
group 3 in order to reach similar exposure in all four groups
(Table 4). With this new model-based dosing regimen, the target
of 8 mg/L for 60% of the dosing interval was reached for.90% of
the patients (i.e. 100%, 98.8%, 99.3% and 99% of the individuals
of groups 1, 2, 3 and 4, respectively).
When compared with the dosing regimen used in this study, a
total daily dose reduction of 67%, 33% and 50% for patients in
groups 1, 2 and 3, respectively, is proposed, resulting in similar
exposure in all groups. The proposed dosing regimen is thus
more in line with some of the recommendations presented in
Table S1. As a consequence of cefazolin dose reduction, albumin
binding places become available for other endogenous (e.g. biliru-
bin) or exogenous compounds competing for the same albumin
binding places. In neonates, frequently showing hyperbilirubinae-
mia (increased bilirubin production and decreased glucuronida-
tion) and/or receiving multidrug therapies, this is a relevant and
population-specific advantage. Recent pharmacokinetic reports
of other b-lactam antibiotics commonly used in neonatal inten-
sive care units also suggested dose adaptations compared with
previously used regimens. To further illustrate this, a reduction
in drug dose and interval for amoxicillin33 and an increase in initial
dose with subsequent dose reduction depending on the microbio-
logical isolate for flucloxacillin37 were suggested in neonates. This
emphasizes the need for population-specific pharmacokinetic
studies in neonates. Since study methodologies can differ, a
250
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Figure 4. Concentration–time profiles based on 1000 Monte Carlo simulations using the final pharmacokinetic model following the dosing regimen used
in this study (upper row), the dosing regimen proposed by the Dutch Children’s Formulary (middle row) and the new model-based proposed dosing
regimen (lower row) in four different groups based on cBW and PNA. The black line represents the median of the simulated profiles and the grey
area represents the 90% CI of the simulated values. The black horizontal line corresponds to the MIC of 8 mg/L. The full grey vertical lines indicate
the time at which 60% of the dosing interval is reached (4.8 and 44.8 h) for a dosing interval of 8 h. The broken vertical lines indicate the time at
which 60% of the dosing interval is reached (7.2 and 43.2 h) for a dosing interval of 12 h.
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correct definition of the pharmacokinetic target is required to
achieve reliable dosing evaluations in this specific population.14,41
In general, we have to be aware that total daily dose reduction of
an antimicrobial may lead to increased bacterial resistance and
ineffectiveness.42 Prospective validation of the new dosing regi-
men is therefore necessary, but this was not the intention of the
present study.
The strength of our analysis is the measurement of both total
and unbound cefazolin concentrations in a relevant neonatal
cohort. Additionally, the final pharmacokinetic model can be
used to optimize dosing regimens for other pathogens in different
settings by changing the target MIC value and/or the T.MIC.
However, there are some limitations. First, the MIC values used
were not prospectively determined. Secondly, the success of anti-
biotic prophylaxis depends not only on selection of the antimicro-
bial drug and drug dosing, but also on correct, well-timed drug
administration and subsequent tissue distribution. Direct meas-
urement of drug concentrations in the surgical site tissues43,44
may provide additional information to include in pharmacokinetic
models, but is very challenging in this population.45
We conclude that total and unbound cefazolin concentrations
in neonates could be described by a one-compartment pharma-
cokinetic model that includes saturable protein binding. bBW and
PNA were defined as the most important covariates contributing
to cefazolin CL variability. A new model-based neonatal cefazolin
dosing regimen was proposed; however, prospective validation of
this dosing regimen is needed.
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